Spectrum to pay TopoTarget $30 million up front for belinostat
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals is to pay TopoTarget $30 million up front for the North American and Indian rights to the novel histone deacetylase inhibitor belinostat.